Effect of Oral Zinc Sulfate Supplementation on Enzymes of Urate Pathway

Effect of Oral Zinc Sulfate Supplementation on Enzymes of Urate Pathway in Spermatozoa and Seminal Plasma of Iraqi Asthenospermic Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03361618

Enrollment

120

Registered

2017-12-05

Start date

2011-07-01

Completion date

2012-06-01

Last updated

2017-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility Unexplained

Keywords

Uric acid, Adenosine deaminase, Zinc Sulfate, 5'-nucleotidase, Asthenospermia., Xanthine oxidase

Brief summary

Although many reports have investigated the relationship between subfertility and uric acid levels in semen, to the best of author knowledge, there is no study have been published to yet focus on the effects of asthenospermia treatments, such as given an oral zinc supplementation, on the activity of urate-related enzymes, which are important in fertility of human.

Detailed description

The present study was designed to investigate the effect of zinc supplementation on the qualitative and quantitative characteristics of semen, along with uric acid levels and urate-related enzymes in the seminal plasma and spermatozoa of asthenospermic males.

Interventions

DIETARY_SUPPLEMENTZinc Sulfate

The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Semen volume after treatment.

Eligibility

Sex/Gender

MALE

Age

26 Years to 36 Years

Healthy volunteers

Yes

Inclusion criteria

* The presence of asthenozoospermia in the semen sample. * Must be unable to reproduce.

Exclusion criteria

* the absence of endocrinopathy, varicocele, and female factor infertility. Smokers and alcoholic men were excluded from the study because of their recognized high seminal ROS levels and decreased antioxidant levels.

Design outcomes

Primary

Measure	Time frame	Description
Measurement the uric acid level in spermatozoa and seminal plasma by using spectrophotometer.	up to three months.	Clinical parameter

Secondary

Measure	Time frame	Description
Measurement the adenosine deaminase activity in spermatozoa and seminal plasma by using spectrophotometer.	up to three months.	Enzyme
Measurement the xanthine oxidase activity in spermatozoa and seminal plasma by using spectrophotometer.	up to three months.	Enzyme
Measurement the 5'-nucleotidase activity in spermatozoa and seminal plasmaby using the spectrophotometer.	up to three months.	Enzyme

Countries

Iraq

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026